Is Aptorum Group Limited (APM) a Buy, Sell, or Hold?
Aptorum Group Limited
NASDAQ:APM
$0.8148 USD
$0.0 (0.59%)
- Volume
- 16.62K
- Average Volume
- 135.32K
- Market Capitalization
- $5.17M
- P/E Ratio
- -4.24
- Dividend Yield
- 0.00%
- Price Target
- $
- Year High
- $4.47
- Year Low
- $0.65
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.78
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Ian Huen |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | APM |
| CUSIP | G6096M122 |
| CIK | 0001734005 |
| Web | https://www.aptorumgroup.com |
| Phone | 44 20 8092 9299 |
| Currency | USD |
| Employees | 2 |
| Country | GB |
Liquidity
| Debt-to-Equity Ratio | 0.15 |
| Payout Ratio | 0.00 |
| Current Ratio | 0.78 |
| Quick Ratio | 0.78 |
| Cash Ratio | 0.75 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 0.00 |
| Cash Flow | 0.00 |
| Price / Cash Flow | 0.00 |
| Price / Book | 0.26 |
Price Target and Rating
| Average Stock Price Forecast | $ |
| High Stock Price Forecast | $ |
| Low Stock Price Forecast | $ |
| Forecast Upside/Downside | % |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 2 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-0.19 |
| Trailing P/E Ratio | -4.24 |
| PEG Ratio | -0.03 |
| P/E Growth | -0.03 |
| Net Income | $-1.36M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -5.90% |
| Return on Assets | -7.29% |
Financials Score
| AltmanZ Score | -5.99 |
| Piotroski Score | 1.00 |
| Working Capital | -1M |
| Total Assets | 18.69M |
| Ebit | -5.83M |
| Market Cap | 5.14M |
| Total Liabilities | 4.9M |
Poll Results
About Aptorum Group Limited (NASDAQ:APM) Stock
Aptorum Group Limited, through its subsidiaries, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small molecule, which is in phase 1 clinical trial for the treatment of bacterial infections, such as staphylococcus aureus, mycobacterium tuberculosis, and pseudomonas aeruginosa; and RPIDD, a liquid biopsy rapid pathogen diagnostic which is in preclinical trial to treat pathogen molecular diagnostics. The company also develops SACT-COV19, a repurposed small molecule which is in preclinical trial for the t ... reatment of coronavirus disease; SACT-2 and SACT-3; ALS-1, a small molecule which is in preclinical trial to treat bacterial infections caused by staphylococcus aureus, including methicillin-resistant staphylococcus aureus (MRSA); and ALS-2/3, a small molecule which is in preclinical trial for the treatment of gram+ve bacterial infections. In addition, it is developing NLS-1, which is in preclinical trial for the treatment of endometriosis; DLS-1+2, which is in preclinical trial to treat NSCLC with mutation; DLS-3, which is in preclinical trial to treat autoimmune disease; CLS-1, a macromolecule, which is in preclinical trial to treat obesity; and CLS-1 and CLS-3. Further, the company offers NativusWell DOI (NLS-2), a dietary supplement for women undergoing menopause; and provides management services. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom.
2026-07-08 08:00:00
NEW YORK, NY; NEW HAVEN, CT; and PRINCETON, NJ, July 08, 2026 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs, and DiamiR Biosciences (“DiamiR”), a developer of innovative blood-based diagnostic tests for brain health and other diseases, today announced upcoming presentations at the annual Alzheimer's Association International Conference (AAIC), taking place at the Excel London Convention & Exhibition Centre, in London, UK, and online, on July 11-15, 2026, showcasing biomarker technologies from DiamiR's CLIA-certified, CAP-accredited clinical laboratory. Alidad Mireskandari, Ph.D.
2026-06-22 08:00:00
NEW YORK, NY; NEW HAVEN, CT; and PRINCETON, NJ, June 22, 2026 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs. and DiamiR Biosciences Corp. (“DiamiR”), a developer of innovative blood-based diagnostic tests for brain health and other diseases, today announced a collaboration between DiamiR and AlzLabs Precision Diagnostics (“AlzLabs”) to generate protein and microRNA blood-based biomarker data with the focus on Alzheimer's disease.
Statement in Response to Silver Elephant's News Release Dated June 17, 2026
2026-06-18 17:29:00
Toronto, Ontario--(Newsfile Corp. - June 18, 2026) - Andean Precious Metals Corp. (TSX: APM) (OTCQX: ANPMF) ("Andean" or the "Company") is aware of the news release issued by Silver Elephant Mining Corp. ("Silver Elephant") on June 17, 2026, regarding its filing of a Notice of Civil Claim in Vancouver, British Columbia. The allegations contained in Silver Elephant's news release and its Notice of Civil Claim are spurious and wholly without merit, and Andean strongly disagrees with Silver Elephant's characterization of the facts and circumstances described therein.
Aptorum Group Announces Shareholder Approval of Proposed Merger with DiamiR Biosciences
2026-06-10 08:00:00
NEW YORK, NY, June 10, 2026 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group" or "Aptorum"), a biopharmaceutical company dedicated to addressing unmet medical needs, today announced that at its shareholder meeting held on June 9, 2026, its shareholders voted to approve the proposed merger transaction with DiamiR Biosciences Corp. (“DiamiR”), a developer of innovative blood-based diagnostic tests for brain health and other diseases.
Andean Precious Metals Corp. (APM:CA) Q1 2026 Earnings Call Transcript
2026-05-13 13:10:51
Andean Precious Metals Corp. (APM:CA) Q1 2026 Earnings Call Transcript
Head-To-Head Survey: Aptorum Group (NASDAQ:APM) versus Catalyst Pharmaceuticals (NASDAQ:CPRX)
2026-04-16 01:11:07
Aptorum Group (NASDAQ: APM - Get Free Report) and Catalyst Pharmaceuticals (NASDAQ: CPRX - Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, dividends and risk. Risk and Volatility Aptorum Group has a beta
Frequently Asked Questions
-
What is the current Aptorum Group Limited (APM) stock price?
-
Aptorum Group Limited(NASDAQ:APM) stock price is $0.8148 in the last trading session. During the trading session, APM stock reached the peak price of $4.47 while $0.65 was the lowest point it dropped to. The percentage change in APM stock occurred in the recent session was 0.59% while the dollar amount for the price change in APM stock was $0.0.
-
APM's industry and sector of operation?
-
The NASDAQ listed APM is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of APM?
-
Kwok Kuen Wong | Head of Finance
Chung Yuen Huen | Founder, Chief Executive Officer & Executive Director
|
|
| -
How many employees does APM have?
-
Number of APM employees currently stands at 2. APM operates from 17 Hanover Square, London, GL W1S 1BN, GB.
-
Link for APM official website?
-
Official Website of APM is: https://www.aptorumgroup.com
-
How do I contact APM?
-
APM could be contacted at phone #44 20 8092 9299 and can also be accessed through its website. APM operates from 17 Hanover Square, London, GL W1S 1BN, GB.
-
How many shares of APM are traded daily?
-
The average number of APM shares traded daily for last 3 months was 135.32K.
-
What is the market cap of APM currently?
-
The market value of APM currently stands at $5.17M with its latest stock price at $0.8148